AlphaRx and Riso Pharma Sign Collaboration and Licensing Agreement

MARKHAM, ON, Sept. 30 /PRNewswire-FirstCall/ - AlphaRx Inc., has entered into an exclusive collaboration and licensing agreement with Riso Pharma Tech for the development of ARX606T, an early stage product candidate intended for wound treatment. Under the terms of the agreement, AlphaRx will give Riso exclusive global rights (with the exception of Asia) of ARX606T, which makes use of AlphaRx's proprietary formulation technology to deliver a safe and well known growth factor topically to patients with severe wounds and ulcers. AlphaRx will earn a double digit royalty on future sales of ARX606T in all countries covered by the agreement and Riso will be responsible for all clinical development and commercialization activities."Earlier this year we set ourselves the goal of securing research collaborations to fund our research activities. In August we announced a collaboration with Venturepharm and today we are delighted to announce this licensing agreement with Riso Pharma," said Michael Lee, President & CEO of AlphaRx Inc. "The licensing agreement is in line with our early-stage partnering business strategy which not only reduces development costs but also allows the company to earn significant revenues from successful product commercialization."About AlphaRx Inc.AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.About Riso Pharma TechRiso Pharma Tech is a Canadian-based affiliate of a large Holding Company: Riso Holding, based in Tehran, Iran. As a group, Riso has sole agency agreements with some of the largest pharmaceutical companies in the world f...
Click here to read the whole Article (external link)

AlphaRx Presents Company Overview and New Product Candidates at the Rodman Renshaw Healthcare Conference

MARKHAM, ON, Sept. 14 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB: ALRX - News). Speaking at the 11th Annual Rodman Renshaw Healthcare Conference in New York City, AlphaRx Director Dr. David Milroy presented a company overview focusing on the Company's product pipeline, nano drug delivery platform and the significant developments anticipated within the next 12 months. In Summary, AlphaRx will have 3-4 products in different stages of clinical development by the end of 2010, which have major market indications and opportunities, producing a portfolio of short to long term drug candidates to position the company for stable and sustainable growth. In addition, AlphaRx presented 2 new product candidates ARX1088 and ARX2038 which are being developed for herpes and lipid management respectively. These products have excellent safety profile and have over 25 years of successful clinical applications outside the US. AlphaRx is developing a new dosage form for ARX1088 and ARX2038 and planning to initiate Phase II clinical trails in the later part of 2010. About ARX1088The active ingredient in ARX1088 is an orally active interferon inducer. It primarily acts as an inducer of type I, alpha or beta interferon. In humans, these interferon levels double as early as four hours after administration of the drug. After 12-24 hours the levels can be one hundred or even several thousand fold higher, with maximum level achieved at 48 hours. It is a drug that is currently approved to treat certain anti-viral indications outside USA. ARX108...
Click here to read the whole Article (external link)

ALPHARX INC Financials

Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback Quotes delayed, except where indicated otherwise.Delay times are 15 mins for NASDAQ, 20 mins for NYSE and Amex. See also delay times for other exchanges.Fundamental company data provided by Capital IQ. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. Real-...
Click here to read the whole Article (external link)

ALPHARx to Present at Rodman Renshaw Annual Global Investment Conference

MARKHAM, ON, Sept. 3 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB: ALRX - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, today announced that it is scheduled to make an investor presentation at the Rodman Renshaw Annual Global Investment Conference at 2:25 pm EDT on Friday, September 11, 2009. The conference will be held at the New York Palace Hotel, September 9-11, 2009. AlphaRx will make its presentation in the Spellman Salon (5th Floor) and a live webcast of the presentation will be available via a link provided at http://www.wsw.com/webcast/rrshq15/alrx . An archived replay of the presentation will be available for a period of 90 days from the date of the presentation.About AlphaRx Inc.AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development. For more information, please visit ...
Click here to read the whole Article (external link)

AlphaRx Concludes GAI-122 Formulation Development Intended For The Prevention of Delirium

MARKHAM, ON, Aug. 27 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX - News) and Gaia BioPharma Limited announce an update on their programme to develop a preventive treatment for delirium caused by prolonged surgery. Each year in the United States, as many as 7 million hospitalized adults experience delirium, a state of confusion caused by a sudden alteration of mental status. Currently, there are no approved drugs available in the United States to prevent or manage delirium. "Developing post-operative delirium prolongs the length of a patient's hospital stay, increases the risk of post-hospitalization transfer to a nursing home and doubles the risk of death. As the national burden of delirium to the health care system may be as high as $152 billion annually, there is an urgent need to identify a safe and effective drug therapy to reduce the incidence of delirium and its' associated health care costs," said Dr. Peter Carlen, a clinical neurologist collaborating with AlphaRx in the GAI-122 delirium program.GAI-122 is proceeding to the clinical trial materials manufacturing stage and is expected to enter clinical trials by mid-2010. GAI-122 is protected by 4 US patent applications.In October 2008, AlphaRx licensed GAI-122 to Gaia BioPharma. Under the terms of the amended agreement, AlphaRx is eligible to receive milestone payments of up to $50 million for the successful development and commercialization of GAI-122, as well as royalties on worldwide sales. In addition, Gaia BioPharma assumes all development cost...
Click here to read the whole Article (external link)

ALPHARX INC Files SEC form 10-Q, Quarterly Report

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATION The following discussion and analysis should be read in conjunction with the Financial Statements, including the condensed Notes thereto, appearing in this Form 10-Q. For additional information and complete financial statement note disclosure as of September 30, 2008, reference should be made to the annual Form 10-K filed during December 2008. Except for the historical information contained herein the foregoing discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those projected in the forward-looking statements discussed herein. General AlphaRx, Inc. is a drug delivery company specializing in the development and improvement of FDA approved drugs by reformulating drugs via the application of its proprietary site-specific nano drug delivery technology. Our core competence is in the development of novel drug formulations for therapeutic molecules or compounds that have exhibited poor gastro intestinal absorption due to poor solubility or have yet be administerable to the human body with an acceptable delivery method. Our drug delivery system -Bioadhesive Colloidal Dispersion ("BCD™") drug delivery system is versatile and offers significant flexibility in the development of suitable dosage formulations (i.e. oral, topical or parenteral) to meet the requirements of specific drug molecules. Drugs reformulated with our technology provide drug manufacturers with the potential to extend patent protection for existing drugs. We no longer pursue direct commercialization of our products via advanced clinical trials, marketing and sales nor do we intend to pursue such activities of any newly developed product candidates. The absence of significant ongoing funding required to obtain necessary FDA and other country approvals and promote a product successfully into the market are the principal fac...
Click here to read the whole Article (external link)

ALPHARX INC Files SEC form 10-Q, Quarterly Report

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATION The following discussion and analysis should be read in conjunction with the Financial Statements, including the condensed Notes thereto, appearing in this Form 10-Q. For additional information and complete financial statement note disclosure as of September 30, 2008, reference should be made to the annual Form 10-K filed during December 2008. Except for the historical information contained herein the foregoing discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those projected in the forward-looking statements discussed herein. General AlphaRx is a drug delivery company specializing in the development of innovative human therapeutic products for the pharmaceutical and consumer health care market. Our core competence is in the development of novel drug formulations for therapeutic molecules or compounds that have exhibited poor gastro intestinal absorption due to poor solubility or have yet be administerable to the human body with an acceptable delivery method. Our drug delivery system is versatile and offers significant flexibility in the development of suitable dosage formulations (i.e. oral, topical or parenteral) to meet the requirements of specific drug molecules. We are no longer pursuing direct marketing and sales of our market ready products, nor do we intend to pursue direct marketing and commercialization of any newly developed products. The absence of marketing expertise, and significant ongoing funding required to introduce and promote a product successfully into the market are the principal factors limiting our ability to directly market our proprietary products. We are and will continue to seek out established collaborative partners, distributors and licensees to commercialize and market our products in exchange for milestone payments and royalties. The costs incurred for individ...
Click here to read the whole Article (external link)

ALPHARX INC Files SEC form 10-Q, Quarterly Report

ITEM 2: MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATION The following discussion and analysis should be read in conjunction with the Financial Statements, including the condensed Notes thereto, appearing in this Form 10-Q. For additional information and complete financial statement note disclosure as of September 30, 2008, reference should be made to the annual Form 10-K filed during December 2008. Except for the historical information contained herein the foregoing discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those projected in the forward-looking statements discussed herein. General AlphaRx is a drug delivery company specializing in the development of innovative human therapeutic products for the pharmaceutical and consumer health care market. Our core competence is in the development of novel drug formulations for therapeutic molecules or compounds that have exhibited poor gastro intestinal absorption due to poor solubility or have yet be administerable to the human body with an acceptable delivery method. Our drug delivery system is versatile and offers significant flexibility in the development of suitable dosage formulations (i.e. oral, topical or parenteral) to meet the requirements of specific drug molecules. We are no longer pursuing direct marketing and sales of our market ready products, nor do we intend to pursue direct marketing and commercialization of any newly developed products. The absence of marketing expertise, and significant ongoing funding required to introduce and promote a product successfully into the market are the principal factors limiting our ability to directly market our proprietary products. We are and will continue to seek out established collaborative partners, distributors and licensees to commercialize and market our products in exchange for milestone payments and royalties. The costs incurred for individ...
Click here to read the whole Article (external link)

ALPHARX INC Files SEC form 10-K, Annual Report

ITEM 6. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION The following discussion and analysis should be read in conjunction with the Financial Statements and Notes included in Item 8 of this report. Except for the historical information contained herein the foregoing discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those projected in the forward-looking statements discussed herein. General AlphaRx is a drug delivery company specializing in the development of innovative therapeutic products for the pharmaceutical and consumer health care market. Our core competence is in the development of novel drug formulations for therapeutic molecules or compounds that have exhibited poor gastro intestinal absorption due to poor solubility or have yet be administrable to the human body with an acceptable delivery method. Our drug delivery system is versatile and offers significant flexibility in the development of suitable dosage formulations. Our delivery systems can be adopted to administer drugs orally, topically, or parenterally in order to meet the requirements of specific drug molecules. Please refer to the table under Product Pipeline, Item 1 for the current status of our product research and development activities. The costs incurred for each of these initiatives to date cannot be readily determined because (i) there is no clear distinction between initiatives in order to be able to differentiate between them; (ii) all initiatives have a common goal and that is to adopt our Bioadhesive Colloidal Dispersion ("BCD") drug delivery system to the specific drug in order to improve that drug's effectiveness; and (iii) we do not maintain a time control system to differentiate research and development activities. The nature, timing and estimated costs to complete a project and anticipated completion dates cannot be estimated because: (i) the nature of research is experim...
Click here to read the whole Article (external link)